Adaptive Biotechnologies Corporation(ADPT)

Description: Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

---

Keywords: Cancer Disease Infectious Diseases Drug Discovery Leukemia Diagnostic Tests Blood Test Blood Cancers Minimal Residual Disease Clinical Products Treatment Of A Range Of Cancer Residual Disease

---

Home Page: www.adaptivebiotech.com

ADPT Technical Analysis

1165 Eastlake Avenue East
Seattle, WA 98109
United States
Phone: 206 659 0067

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)